Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) by Abraham, J. et al.
This is a repository copy of Endocrine therapy and related issues in hormone 
receptor-positive early breast cancer: a roundtable discussion by the breast cancer 
therapy expert group (BCTEG).
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/129452/
Version: Published Version
Article:
Abraham, J., Caldera, H., Coleman, R. et al. (11 more authors) (2018) Endocrine therapy 
and related issues in hormone receptor-positive early breast cancer: a roundtable 
discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research 
and Treatment, 169 (1). pp. 1-7. ISSN 0167-6806 
https://doi.org/10.1007/s10549-018-4662-9
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Vol.:(0123456789) 
Breast Cancer Research and Treatment (2018) 169:1–7 
https://doi.org/10.1007/s10549-018-4662-9
REVIEW
Endocrine therapy and related issues in hormone receptor‑positive 
early breast cancer: a roundtable discussion by the breast cancer 
therapy expert group (BCTEG)
Jame Abraham1 · Humberto Caldera2 · Robert Coleman3 · Anthony Elias4 · Matthew P. Goetz5 · Muaiad Kittaneh6  · 
Elyse Lower7 · Reshma Mahtani8 · E. Terry Mamounas9 · Mark Pegram10 · Hope Rugo11 · Lee Schwartzberg12 · 
Tifany Traina13 · Chuck Vogel8
Received: 3 January 2018 / Accepted: 5 January 2018 / Published online: 19 January 2018 
© The Author(s) 2018. This article is an open access publication
Abstract
Purpose Management of breast cancer is a rapidly evolving ield, and, although evidence-based guidelines are available for 
clinicians to provide direction on critical issues in patient care, clinicians often left to address these issues in the context of 
community practice situations with their patients. These include the patient’s comorbid conditions, actual versus perceived 
beneit of treatments, patient’s compliance as well as inancial/reimbursement issues, and long-term tolerability of therapy.
Methods A meeting of global oncology experts was convened in January 2017 with the belief that there is a gap in clinical 
practice guidance on several fundamental issues in breast cancer care, particularly in the community setting, where oncolo-
gists may encounter multiple tumor types. The goal was to discuss some of the most important questions in this area and 
provide some guidance for practicing oncologists.
Results Topics addressed included risk of contralateral breast cancer recurrence in patients with estrogen receptor-positive 
early breast cancer who have undergone 5 years of adjuvant endocrine therapy, adverse events associated with endocrine 
therapy and their management, emergent data on adjuvant bisphosphonate therapy and its apparent beneit in reducing breast 
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cancer recurrence, recent indings of extended adjuvant endocrine therapy trials, and the use of currently available genomic 
biomarker tests as a means of further informing treatment decisions.
Conclusions A summary of the discussion on these topics and several ‘expert opinion statements’ are provided herein in an 
efort to convey the collective insights of the panel as it relates to current standard practice.
Keywords Breast cancer therapy · Expert group · Endocrine therapy · Extended adjuvant therapy · Genomic testing · 
Bisphosphonate therapy
Introduction: about the breast cancer 
therapy expert group (BCTEG) panel
Management of breast cancer is a dynamic and constantly 
evolving ield of oncology. Clinical guidance statements, 
recommendations, and meta-analyses are available for cli-
nicians that provide direction on issues relating to the use 
of adjuvant endocrine therapy, and extended adjuvant (EA) 
endocrine therapy in patients with estrogen receptor-positive 
(ER+), early breast cancer (EBC). Despite these resources, 
however, many issues surrounding the use of, for example, 
EA endocrine therapy, remain unresolved, and clinicians are 
left to address critical questions of care with their patients in 
the context of in-practice clinical considerations, including 
comorbidities, patient’s compliance, actual versus perceived 
beneit of therapies, patient age, inancial/reimbursement 
issues, and tolerability of therapies over the long term.
The breast cancer therapy expert group (BCTEG) panel 
is composed of expert physicians and clinical researchers, 
all of whom have dedicated their careers to the treatment 
of patients with breast cancer and have published exten-
sively on the topics in question. The purpose of convening 
the panel was to discuss important developments related to 
breast cancer management, with a particular emphasis on 
new indings and/or areas where guidance from established 
bodies, such as the National Comprehensive Cancer Net-
work (NCCN) and the American Society for Clinical Oncol-
ogy (ASCO) may be unresolved or less established. The goal 
is to elicit the group’s opinions on the topic as it relates 
to their own clinical practices and, more importantly, how 
this might impact those practicing in the community set-
ting, where multiple tumor types, other than breast cancer, 
are frequently encountered. Importantly, this article is not 
intended to replace any existing guidance or to be an exhaus-
tive review of the topic. Rather, it is intended to present a 
concise synopsis of the relevant data in this area and sum-
marize the consensus opinion of the expert group.
Meeting objectives and role of funding 
sources
A BCTEG meeting was convened in January 2017 with 
the goal of conducting an informal roundtable discussion 
on some of the most important topics related to the use of 
endocrine therapy in the treatment of hormone receptor-
positive EBC. Topics discussed included issues surrounding 
the role of contralateral prophylactic mastectomy (CPM) in 
ER+ EBC, adherence to endocrine therapies, and the use 
of multi-gene assays, which can provide prognostic infor-
mation and guide decisions on systemic adjuvant therapy 
[1–5]. Emergent data regarding the beneits of using adju-
vant bisphosphonates on recurrence and survival outcomes 
in postmenopausal women, as reported by the Early Breast 
Cancer Trialist’s Collaborative Group (EBCTCG) [6], were 
also discussed, as were studies presented at the 2016 San 
Antonio Breast Cancer Symposium (SABCS), which raised 
questions regarding the beneit of using EA endocrine ther-
apy with aromatase inhibitors (AIs) beyond 5 years [7–9]. 
This article is intended to provide a collective summary of 
the participants’ expert opinions on current standard practice 
relating to these issues. An unrestricted educational grant 
for this activity was provided by Biotheranostics, Inc., with 
additional funding provided by Total Health Conferencing, a 
medical education company. The faculty were compensated 
for their participation, and topics of discussion were selected 
by the faculty and by Total Health Conferencing. It is recog-
nized that many of the panelists may have relationships with 
corporate entities, both related and unrelated to the topics in 
question; content of the discussions, and any expert opinions 
presented herein, was intended to be based on the panelists’ 
own expert clinical experience and insight, and is understood 
not to be inluenced by any corporate relationship or interest.
Segment 1: contralateral breast cancer risk
Background
This segment of the discussion was focused on risk reduction 
and contralateral breast cancer events in women with estab-
lished unilateral breast cancer (without risk for hereditary 
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breast or ovarian cancer syndromes) and was aimed at elic-
iting the expert panel’s opinion on estimated annual risk 
of a patient developing a metachronous contralateral breast 
cancer (CBC) from diagnosis, and after receiving 5 years 
of endocrine therapy. Related to this discussion was their 
current assessment of available strategies and/or therapeu-
tic options to reduce CBC risk [i.e., surveillance, contralat-
eral prophylactic mastectomy (CPM), adjuvant hormonal 
therapy], and whether an individual patient’s risk of CBC 
inluenced their recommendations regarding the use of EA 
hormonal therapy.
Discussion
The panel agreed that, based on results from the Oxford 
overview, adjuvant endocrine therapy confers a substantial 
beneit in terms of reducing the risk of CBC for women 
with ER+ disease, and that older estimates of CBC recur-
rence risk at 10–15 years (~ 5 to 8%) are not relective of 
what is seen today, especially for women with ER+ disease 
who have received 5 years of endocrine therapy; as most 
recently gleaned from the NSABP B-42 trial, this risk is 
approximately 3% [7]. Strategies to reduce CBC risk include 
surveillance for a woman with an intact contralateral breast, 
and mammography remains the cornerstone of surveillance. 
American Society for Clinical Oncology (ASCO) guidelines 
recommend mammography once per year, and there is no 
recommendation for MRI or additional functional imaging 
for patients with average risk [5]. Thus, for women with 
ER+ disease taking hormonal therapy, after 5 years, one can 
conidently say that the risk of CBC at least over the next 
10 years is quite low, and the use of CPM in these patients 
would be largely unnecessary. Given the low risk of a CBC 
in years 5 through 10, it was generally agreed that the risk 
of CBC should not weigh heavily into treatment decisions, 
and that discussions for extending adjuvant therapy, at least 
at present, should focus mainly on the risk of distant recur-
rence. In terms of surveillance, panelists were in agreement 
with ASCO guidelines, which recommend yearly mammog-
raphy, with the understanding that more frequent screening 
(i.e., every 6 months) may cause undue anxiety for patients 
and increase costs, and the acknowledgement that studies 
(e.g., MAMMO50) evaluating less frequent schedules have 
completed accrual, and will be reported in the next few years 
[5, 10].
Expert Opinion Statement 1 The use of EA endocrine 
therapy in the context of reducing contralateral breast cancer 
should be highly individualized, and be based on age, as 
well as relevant clinicopathological factors and tolerability. 
Contralateral prophylactic mastectomy is considered largely 
unnecessary in patients with standard risk (i.e., patients 
without history of hereditary breast cancer syndromes), 
given the very low risk of contralateral breast cancer, par-
ticularly in ER+ patients who have received 5 years of initial 
adjuvant endocrine therapy.
Expert Opinion Statement 2 Many patients may be cur-
rently over-screened with every 6-month mammography of 
the afected breast, which can increase patient anxiety and 
costs. Therefore, the panel recommends that the current 
ASCO guidelines for yearly mammographic screening be 
followed.
Segment 2: adverse events and patient 
compliance
Background
This segment of the discussion was focused on adverse event 
management and patient compliance with endocrine therapy, 
with a speciic focus on AIs, and was aimed at eliciting the 
expert panel’s perception of the incidence and impact of 
adverse events (AEs) on compliance. Related to this discus-
sion was the potential impact of patient adherence on treat-
ment outcome, and strategies recommended by the panel 
to manage speciic endocrine therapy-associated AEs such 
as arthralgia, hot lashes, vaginal dryness or atrophy, and 
bone loss.
Discussion
The panelists discussed the deinition of adherence and 
compliance. The term “adherence” could be considered as 
a composite of compliance (i.e., how well the drug regi-
men is followed) and persistence (i.e., how long the patient 
follows the treatment) [2, 11]. In this regard, it was also 
noted that reliable measures of adherence are, for the most 
part, currently lacking. It was agreed that there is consid-
erable discordance between the perception of adherence 
by most clinicians and nonadherence rates as reported in 
clinical trials, in clinical practice, and in medication reill 
record databases [12, 13]. It was acknowledged that lack of 
adherence is associated with poorer survival in the EA set-
ting [14], and that several factors could impact adherence, 
including the physicians themselves (i.e., failure to provide 
a prescription), and patient factors (i.e., failure to ill the 
prescription if given) [15]. AEs, including arthralgia, hot 
lashes, and vaginal dryness or atrophy, are also extremely 
important concerns for patients on AIs. Management strat-
egies discussed included education on life style changes, 
such as exercise, weight reduction, stress management, and 
improving sleep habits. Analgesics were also agreed to be 
efective for the treatment of AI-induced arthralgia. The 
panel also noted vaginal dryness as an underreported and 
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poorly managed side efect of anti-estrogen therapy, which 
must be addressed and managed. It was suggested that topi-
cal nonhormonal vaginal moisturizers and lubricants may 
be used to improve symptoms of vaginal dryness, but per-
sistent gynecologic symptoms may necessitate a discussion 
regarding topical estrogen therapy. In this regard, the panel 
noted that, in some studies, signiicant increases in plasma 
estrogen have been observed with topical estrogen use and 
that concerns over their use in women with breast cancer are 
common [16]. Importantly, however, the panel noted that 
to date no studies have reported an increased risk of breast 
cancer recurrence in patients receiving vaginal estrogens, 
nor has a critical estradiol level been deined that is associ-
ated with higher rates of recurrence in AI-treated women. 
Nevertheless, it was agreed that the use of topical estrogens 
should be based on physician–patient discussions regarding 
individual risk and beneit.
Regarding the issue of bone health, the panel recom-
mended periodic evaluation of bone densitometry and man-
agement of vitamin D deiciency in order to minimize bone 
loss. Depending on bone loss risk factors including personal 
or family history of fracture, smoking, and alcohol usage, 
along with bone densitometry measurements, the use of 
bisphosphonates or denosumab may be indicated [17]. The 
selective serotonin reuptake inhibitors, including duloxetine 
and venlafaxine, can also be considered for symptoms such 
as musculoskeletal pain and hot lashes [18, 19]. In tamox-
ifen-treated women, antidepressants with little or no inhibi-
tion of CYP2D6 should be preferred over antidepressants 
with potent CYP2D6 inhibition activity, as these medica-
tions may result in decreased conversion of tamoxifen to the 
active metabolite, endoxifen. Lastly, changing from one aro-
matase inhibitor to another or to a selective estrogen recep-
tor modulator (i.e., tamoxifen) is another option to improve 
hormone therapy tolerance [20]. The panel agreed that many 
women gather information through internet-based resources 
(including social media) regarding the potential AEs asso-
ciated with AIs and tamoxifen, and that internet bias may 
not provide an accurate risk versus beneit assessment for 
patients. Patient education regarding the beneits (and risks) 
of endocrine therapy is therefore essential to minimize any 
uncertainties or misinformation.
Expert Opinion Statement 1 Education to improve 
patient’s perception of adjuvant endocrine therapy beneit 
and understanding of side efects is a mainstay of improving 
adherence to endocrine therapies.
Expert Opinion Statement 2 Management strategies to 
address side efects related to endocrine therapy should 
include exercise (moderate-intensity physical activity for 
30 min/day, 5 times/week), correcting and maintaining 
vitamin D levels in accordance with current bone health 
guidelines, and use of nonhormonal or, if necessary, hor-
monal topical agents to address vaginal dryness and atrophy; 
analgesics and antidepressants may also be considered for 
arthralgia and hot lashes.
Segment 3: adjuvant bisphosphonates 
and RANK ligand inhibitors
Background
This segment of the discussion was focused on eliciting 
the expert panel’s opinions on the use of adjuvant bispho-
sphonate and RANK ligand (RANK-L) inhibitor therapy 
for reducing risk of breast cancer recurrence. Speciically, 
the panel sought to identify potential candidates for these 
treatments and to evaluate side efect/risk proiles of both 
therapies, and their impact on treatment choices. A related 
line of discussion was whether the decision to ofer patients 
adjuvant bisphosphonate or RANK-L inhibitor therapy 
inluenced the recommendation to also ofer EA hormonal 
therapy.
Discussion
The panel discussion was centered on the results of the 
Oxford meta-analysis, which included nearly 19,000 women, 
approximately 12,000 of whom were postmenopausal [6]. 
In the postmenopausal subset of breast cancer patients, 
bisphosphonate use (of any type, oral or intravenous), pre-
scribed shortly after diagnosis, was associated with highly 
signiicant reductions in all recurrences as well as bone 
recurrences, and in breast cancer mortality, whereas no such 
beneit was seen in the premenopausal subset [6]. The panel 
acknowledged the limitations of applying the results of this 
meta-analysis in terms of obtaining regulatory approval for 
these agents in postmenopausal women. They also acknowl-
edged the comparatively smaller dataset for the RANK-L 
inhibitor denosumab, which was felt at present, to be too 
immature to show a clear beneit in reducing recurrence or 
improving survival. It was suggested, however, that deno-
sumab may be more appropriately used to reduce fracture 
risk, particularly in the EA setting, as the FDA already 
approved denosumab for the treatment of AI-induced bone 
loss [21, 22]. It was agreed by the panel that, in Europe, 
adjuvant bisphosphonates would typically be used in women 
with intermediate to high risk, assuming that they are either 
postmenopausal or on ovarian suppression. Duration of 
treatment in this setting is unclear, but most participants 
used a schedule of every 6 months zoledronic acid (4 mg 
intravenous) for 3 years. By comparison, in the United 
States, the panel agreed that the use of bisphosphonates in 
the adjuvant setting for the purpose of reducing recurrence 
is limited by regulatory obstacles. Bisphosphonates are not 
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presently FDA approved or covered by insurance for this 
indication and currently their use is approved only for those 
patients who have continued bone loss after receiving irst-
line oral bisphosphonates (i.e., alendronate). There are no 
data to suggest intervention with a bone-targeted agent in 
the context of EA therapy will reduce late recurrence, and 
therefore the decision to ofer a bone-targeted therapy was 
not though the inluence the decision to ofer EA therapy.
Expert Opinion Statement 1 Setting aside issues with reg-
ulatory approval and payers/reimbursement, given evidence 
for a beneit of adjuvant bisphosphonates in reducing recur-
rence, distant recurrence, and improving survival in post-
menopausal women receiving adjuvant endocrine therapy, 
adjuvant bisphosphonates can be considered for women with 
early-stage breast cancer.
Expert Opinion Statement 2 Notwithstanding a lack of 
demonstrated survival beneit, a RANK-L inhibitor, deno-
sumab, may be considered for patients receiving adjuvant 
endocrine therapy in view of its approved indication for pre-
venting bone loss in patients receiving AIs.
Segment 4: current perspectives on the use 
of multi‑gene assays and duration 
of endocrine therapy
This segment of the discussion was focused on the current 
guidelines regarding the use of multi-gene assays and was 
aimed at eliciting the expert panel’s opinion on the optimal 
duration of adjuvant endocrine therapy for patients with hor-
mone receptor-positive early breast cancer and, speciically, 
whether there is a clinically meaningful beneit of extending 
AI-based endocrine therapy to 10 years for selected patients. 
Related to this discussion was the panel’s current recom-
mendation for stratifying patients for EA endocrine therapy 
(i.e., do they currently use clinicopathologic features with 
or without genomic assays for this purpose).
Discussion
The panel discussion was centered on the new guidelines 
on multi-gene assays from ASCO, which were noted to 
have deviated somewhat from the initial guidance on this 
topic, and some inconsistencies between these guidelines 
and those of the National Comprehensive Cancer Network 
(NCCN) were also noted (e.g., for node-positive patients). 
The panel noted the absence of emergent data from key tri-
als, particularly MINDACT [23] in the 2016 ASCO guid-
ance on biomarkers [3], and suggested that, due to the rapid 
advances in this ield, updates in this guidance should occur 
more frequently. The panel agreed that multi-gene assays do 
provide important information, which can be useful when 
communicating recurrence risk and benefits of therapy 
with the patients. For example, if chemotherapy can reduce 
recurrence risk by 30%, one could safely recommend the 
treatment if recurrence risk was ~ 50%; by comparison, if 
recurrence risk was only 10–15% for a given patient, the 
small absolute beneit from chemotherapy would certainly 
be outweighed by the risk of intervention [3, 24]. There was 
agreement that further validation studies are needed and that 
tumor biology (as revealed by multi-gene assays) must also 
be considered in the continuum of other clinicopathologic 
factors.
In view of recently reported results from SABCS, par-
ticipants agreed that the beneit of EA endocrine therapy is, 
overall, modest, and some participants cited the need for a 
meta-analysis of all EA endocrine studies that could provide 
further clariication on the issue. For example, as reported 
in the NSABP-42 study, disease-free survival at ~ 7 years 
was 84.7 and 81.3% for patients on extended adjuvant AI 
(letrozole) and placebo groups, respectively (3.4% absolute 
beneit), and the diference did not technically reach statis-
tical signiicance, due to adjustments for interim analyses 
(hazard ratio = 0.85, P = 0.048; P value for signiicance 
set at 0.0418) [7]. In view of these and other results, there 
is a need to more efectively identify patients most likely 
to beneit from EA endocrine treatment. To this end, the 
panel recognized the availability of several genomic bio-
marker tests which, in conjunction with clinicopathologic 
factors, may provide additional prognostic information on 
recurrence risk; these include Oncotype Dx, Breast Cancer 
Index (BCI), PAM 50 Risk of Recurrence (ROR), EndoPre-
dict, and MammaPrint [3]. All of these tests can be useful 
to identify patient subsets that have an extremely low risk of 
recurrence. The PAM 50 ROR score, for example, has been 
shown to provide additional prognostic information over and 
above standard clinical factors on risk of distant recurrence 
in the ABCSG 8 trial [25], and Level 1 evidence supporting 
the use of the 70-gene signature (MammaPrint) to further 
inform decisions on avoiding the use of adjuvant chemo-
therapy has also recently been published from the MIND-
ACT trial [23]. Many of the participants reported using the 
21-gene Oncotype Dx Recurrence Score (RS) to help inform 
their decisions on the use of adjuvant chemotherapy in node-
positive (1–3 lymph nodes) and node-negative ER+ patients, 
in the context of other clinicopathologic factors. While 
again citing the need for additional validation, at least one 
of these tests, BCI, has also been shown to predict response 
to endocrine therapy, and many participants reported hav-
ing used BCI, at least on occasion (or more frequently) to 
further inform their treatment decisions for patients whose 
need for an additional 5 years of endocrine therapy was less 
certain (most notably, node-negative patients) [26–28]. It 
was also acknowledged that major cancer staging manuals, 
such as the American Joint Commission on Cancer (AJCC) 
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forthcoming 8th Edition, have already incorporated these 
multi-gene panels into their risk assessment models.
Expert Opinion Statement 1 Although further validation 
studies are needed, the use of multi-gene assays may provide 
important additional information that can guide treatment 
decisions; this information should be considered in the con-
text of other clinicopathologic factors.
Expert Opinion Statement 2 Recently reported results 
from EA endocrine therapy trials suggest an overall modest 
beneit of extending endocrine therapy beyond 5 years; the 
currently available genomic biomarker assays may be use-
ful to further inform treatment decisions in patients where 
uncertainty may exist (e.g., node-negative and/or poor 
tolerability).
Conclusion
In the face of emergent clinical trial data, optimal treatment 
for patients with early breast cancer will continue to evolve. 
The panel recognized the limitations of current guidance 
surrounding the use of EA endocrine therapy for patients 
with ER+ disease, and the importance of future discussions 
on this topic. They also recognize the importance of forth-
coming data that will further inform treatment decisions in 
this area. Until such data become available, however, the 
panel recommends a highly individualized approach, with 
shared patient–physician decision-making, and a strong 
emphasis on patient education to help improve adherence 
and persistence when selecting patients for CPM, EA endo-
crine therapy, and/or adjuvant bisphosphonate treatment.
Note added in proof
Shortly after this expert roundtable meeting was convened, 
a guideline statement was published by a joint Cancer Care 
Ontario (CCO)/ASCO working group and expert panel, 
which ofers recommendations on the use of adjuvant bis-
phosphonates in postmenopausal women undergoing sys-
temic adjuvant therapy for breast cancer. (http ://asco pubs 
.org/doi/full /10.1200 /JCO.2016 .70.7257 ) The reader is 
referred to this statement for further guidance and clariica-
tion on this issue. In addition, the authors note the recently 
published focused update of the ASCO guidance on the use 
of biomarkers which details the results from MINDACT 
supporting the use of MammaPrint to inform decisions 
on avoiding the use of systemic adjuvant chemotherapy in 
women with high-clinical risk and low-genomic risk early-
stage invasive ER+ breast cancer. (http ://asco pubs .org/doi/
pdf/10.1200 /JCO.2017 .74.0472 ).
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